092730 — NeoPharm Co Share Price
0.000.00%
Last trade - 00:00- KR₩182bn
- KR₩71bn
- KR₩97bn
- 84
- 64
- 66
- 87
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 8.12 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -0.83% | ||
| Dividend Yield (f) | 3.01% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.14 | ||
| Price to Tang. Book | 1.15 | ||
| Price to Free Cashflow | 74.68 | ||
| Price to Sales | 1.87 | ||
| EV to EBITDA | 2.63 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.76% | ||
| Return on Equity | 15.36% | ||
| Operating Margin | 26.05% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 83,240.33 | 81,625.35 | 87,930.72 | 85,033.14 | 97,104.89 | 119,300 | 135,900 | 7.94% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +19.72 | -10.67 | -1.36 | -3.98 | +36.34 | -8.73 | +18.98 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NeoPharm Co., Ltd. is a Korea-based company engaged in the manufacture of cosmetics. The Company produces its products under brand names of ATOPALM, including daily care, intensive care, special care and baby care products; Derma:B, including foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, blemish base (BB) creams, sun protectors, white watering serums, anti-aging eye creams and others; ZEROID, including creams and lotions for recovering damaged skin barriers and hypollalergenic foaming cleansers for atopy and sensitive skins, and others. It also engages in the original equipment manufacturing (OEM) of skin drugs.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 1st, 2000
- Public Since
- January 30th, 2007
- No. of Shareholders
- 14,673
- No. of Employees
- 94
- Sector
- Personal & Household Products & Services
- Industry
- Consumer Defensives
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 7,820,628
- Address
- 309-8, Techno 2-ro, Yuseong-gu, DAEJEON, 34037
- Web
- https://neopharm.co.kr/ko/default.do
- Phone
- +82 428640038
- Auditors
- Sahmduk Accounting Corp.
Upcoming Events for 092730
Q2 2024 NeoPharm Co Ltd Earnings Release
Similar to 092730
Barunson Co
Korea Exchange - KOSDAQ
BeautySkin Co
Korea Exchange - KOSDAQ
Bonne Co
Korea Exchange - KOSDAQ
C&C International Co
Korea Exchange - KOSDAQ
Clio Cosmetics Co
Korea Exchange - KOSDAQ
FAQ
What is the NeoPharm Co share price?
As of Today at 19:15 UTC, shares in NeoPharm Co are trading at KR₩23,250. This share price information is delayed by 15 minutes.
How has the NeoPharm Co share price performed this year?
Shares in NeoPharm Co last closed at KR₩23,250 and the price had moved by +28.81% over the past 365 days. In terms of relative price strength the NeoPharm Co share price has outperformed the FTSE Developed Asia Pacific Index by +34.45% over the past year.
What are the analyst and broker recommendations for NeoPharm Co?
The overall consensus recommendation for NeoPharm Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the NeoPharm Co dividend yield?
The NeoPharm Co dividend yield is 3.23% based on the trailing twelve month period.
Does NeoPharm Co pay a dividend?
Last year, NeoPharm Co paid a total dividend of KR₩750, and it currently has a trailing dividend yield of 3.23%. We do not have any data on when NeoPharm Co is to next pay dividends.
When does NeoPharm Co next pay dividends?
We do not have data on when NeoPharm Co is to next pay dividends. The historic dividend yield on NeoPharm Co shares is currently 3.23%.
How do I buy NeoPharm Co shares?
To buy shares in NeoPharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of NeoPharm Co?
As of the previous close price of KR₩23,250, shares in NeoPharm Co had a market capitalisation of KR₩182bn.
Where are NeoPharm Co shares listed?
Here are the trading details for NeoPharm Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 092730
What kind of share is NeoPharm Co?
Based on an overall assessment of its quality, value and momentum NeoPharm Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a NeoPharm Co share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the NeoPharm Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NeoPharm Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -12.99%.
As of the last closing price of KR₩23,250, shares in NeoPharm Co were trading -6.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the NeoPharm Co PE Ratio?
The NeoPharm Co PE ratio based on its reported earnings over the past 12 months is 8.12. The shares last closed at KR₩23,250.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of NeoPharm Co?
NeoPharm Co's management team is headed by:
- Dae Yeol Lee - CEO
- Hang Sik Bae - OTH
- Seok Ju Lee - OTH
- Gwang Hyeon Goh - NID